Call Us : 1.224.938.9523 meetings@worldeventsforum.com

Public Education Forum

THE ANNUAL ALZHEIMER’S PUBLIC EDUCATIONAL FORUM
Sunday, April 2 (1:00 pm – 4:30 pm US Eastern Time)

The event is free-for-all and will be held online via Zoom.

NOTE: This event will not offer CME/CE credits.

ACCESS INFORMATION

The event will be accessible through the individual* Zoom link provided upon registration. This link should arrive upon registration,  the day before and an hour before the start time.

If you cannot locate this email, please check your spam folder! If not found there either, please contact our secretariat so we can manually re-issue this information. 

2023 Alzheimer’s Disease Public Educational Forum

CHAIRS:
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine

This event is intended for the public at large, including individuals at-risk for AD, their family members, as well as professionals from various fields who may be interested in an up-to-date review of some aspects of AD research.

The FDA has provided accelerated approvals for the first time for two disease-modifying drugs for Alzheimer’s disease. These two drugs, and one additional drug which is expected to receive accelerated approval in 2023, are monoclonal antibody treatments, designed to remove the toxic beta amyloid protein, associated with Alzheimer’s disease, from the brain.

In this Public Information Forum our goal is to provide information and answer questions about this new class of drugs for Alzheimer’s disease, from six experts in the field. The topics which will be addressed include:

1. clarification about how the treatment works and modifies the course of Alzheimer’s disease and its symptoms,

2. the clinical meaningfulness of the reported extent of slowing of progression of the disease,

3. the side effect profile of the approved drug,

4. the expected duration of treatment and how to determine when to stop treatment,

5. the contraindications for treatment with these drugs,

6. the alternatives to treatment with this new generation of drugs, and

7. the balance between efficacy, side effects, cost of treatment and guidance (for a particular patient) about how to proceed.

Sunday, APRIL 2, 2023

All times in US Eastern Time

 

PRELIMINARY PROGRAM

1:00pm ET
Introductory Notes
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center, Miami Beach, FL
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine, Miami, FL
1:05
Introduction to Dementia, MCI, Alzheimer’s Disease, Amyloid, Tau and Neurodegeneration
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center, Miami Beach, FL
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine, Miami, FL
1:20
Questions and Discussion
Questions and Discussion
1:30
Drugs likely to Receive Full FDA Approval in 2023/24: Efficacy, Adverse Effects, Mode of Delivery, Cost
Howard Feldman, MD, University of California, San Diego, San Diego, CA
1:45
Questions and Discussion
Questions and Discussion
1:55
The Clarity Trial with Lecanemab for Alzheimer’s Disease
Christopher Van Dyck, MD, Yale University School of Medicine
2:10
Questions and Discussion
Questions and Discussion
2:20
Non-Pharmacological Options for Treatment
Arlener Turner, PhD,University of Miami, Miami, FL
2:35
Questions and Discussion
Questions and Discussion
2:45
Treatment options, Ethical Issues and Decision Making
Jason Karlawish, MD, Perelman School of Medicine, Philadelphia, PA
3:00
Questions and Discussion
Questions and Discussion
3:10
Summary Discussion
David Knopman, MD, Mayo Clinic, Rochester, MN
3:25
Concluding Remarks
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center, Miami Beach, FL
4:00
Forum Ends